CA2466800A1 - Modulation of ocular growth and myopia by gaba drugs - Google Patents
Modulation of ocular growth and myopia by gaba drugs Download PDFInfo
- Publication number
- CA2466800A1 CA2466800A1 CA002466800A CA2466800A CA2466800A1 CA 2466800 A1 CA2466800 A1 CA 2466800A1 CA 002466800 A CA002466800 A CA 002466800A CA 2466800 A CA2466800 A CA 2466800A CA 2466800 A1 CA2466800 A1 CA 2466800A1
- Authority
- CA
- Canada
- Prior art keywords
- eye
- gaba
- growth
- eyes
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 126
- 239000003814 drug Substances 0.000 title claims abstract description 126
- 230000012010 growth Effects 0.000 title claims abstract description 103
- 208000001491 myopia Diseases 0.000 title claims abstract description 64
- 230000004379 myopia Effects 0.000 title claims abstract description 60
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 84
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 59
- 239000005557 antagonist Substances 0.000 claims abstract description 56
- 239000000556 agonist Substances 0.000 claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 238000011161 development Methods 0.000 claims abstract description 28
- 206010020675 Hypermetropia Diseases 0.000 claims abstract description 24
- 201000006318 hyperopia Diseases 0.000 claims abstract description 24
- 230000004305 hyperopia Effects 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 201000009487 Amblyopia Diseases 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims description 71
- 241001465754 Metazoa Species 0.000 claims description 49
- 230000002207 retinal effect Effects 0.000 claims description 49
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical group NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 claims description 40
- 230000018109 developmental process Effects 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 102000005915 GABA Receptors Human genes 0.000 claims description 22
- 108010005551 GABA Receptors Proteins 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 229940044551 receptor antagonist Drugs 0.000 claims description 19
- 239000002464 receptor antagonist Substances 0.000 claims description 19
- 230000001722 neurochemical effect Effects 0.000 claims description 16
- 102000027484 GABAA receptors Human genes 0.000 claims description 15
- 108091008681 GABAA receptors Proteins 0.000 claims description 15
- MFUKVPOVVKKLRQ-UHFFFAOYSA-N methyl(1,2,3,6-tetrahydropyridin-1-ium-4-yl)phosphinate Chemical group CP(O)(=O)C1=CCNCC1 MFUKVPOVVKKLRQ-UHFFFAOYSA-N 0.000 claims description 15
- 239000003085 diluting agent Substances 0.000 claims description 13
- 239000000018 receptor agonist Substances 0.000 claims description 12
- 229940044601 receptor agonist Drugs 0.000 claims description 12
- 241000288906 Primates Species 0.000 claims description 11
- 230000004323 axial length Effects 0.000 claims description 11
- XOESDNIUAWGCLU-UHFFFAOYSA-N 3-aminopropyl(cyclohexylmethyl)phosphinic acid Chemical group NCCCP(O)(=O)CC1CCCCC1 XOESDNIUAWGCLU-UHFFFAOYSA-N 0.000 claims description 9
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical group OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 9
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 229960000794 baclofen Drugs 0.000 claims description 8
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 claims description 8
- 230000009596 postnatal growth Effects 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims description 6
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims description 6
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 claims description 4
- 229940121909 GABA receptor agonist Drugs 0.000 claims description 4
- 229940098788 GABA receptor antagonist Drugs 0.000 claims description 4
- SEYCKMQSPUVYEF-LURJTMIESA-N sch-50911 Chemical compound CC1(C)CO[C@@H](CC(O)=O)CN1 SEYCKMQSPUVYEF-LURJTMIESA-N 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000004515 progressive myopia Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000003140 4 aminobutyric acid A receptor blocking agent Substances 0.000 claims 2
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 claims 2
- 239000003412 4 aminobutyric acid B receptor blocking agent Substances 0.000 claims 2
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims 2
- 229940123431 GABA B receptor agonist Drugs 0.000 claims 2
- 229940119207 GABA B receptor antagonist Drugs 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000008927 postnatal maturation Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 45
- 108020003175 receptors Proteins 0.000 description 45
- 239000003981 vehicle Substances 0.000 description 37
- 210000001525 retina Anatomy 0.000 description 33
- 238000002604 ultrasonography Methods 0.000 description 22
- 238000000540 analysis of variance Methods 0.000 description 20
- 238000011282 treatment Methods 0.000 description 17
- 238000005259 measurement Methods 0.000 description 16
- 238000010162 Tukey test Methods 0.000 description 15
- 230000007246 mechanism Effects 0.000 description 15
- 210000002159 anterior chamber Anatomy 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000000007 visual effect Effects 0.000 description 13
- 230000000857 drug effect Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000004438 eyesight Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000004575 stone Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 208000014733 refractive error Diseases 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 210000000411 amacrine cell Anatomy 0.000 description 5
- 230000004329 axial myopia Effects 0.000 description 5
- 229940012356 eye drops Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004373 eye development Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 208000003098 Ganglion Cysts Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005400 Synovial Cyst Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003445 gaba agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000001116 retinal neuron Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- BDFAOUQQXJIZDG-UHFFFAOYSA-N 2-methylpropane-1-thiol Chemical compound CC(C)CS BDFAOUQQXJIZDG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 108010086407 GABA-C receptor Proteins 0.000 description 2
- 102000056764 GABAA-rho receptor Human genes 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241001123946 Gaga Species 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- QIIVUOWTHWIXFO-UHFFFAOYSA-N cgp-35348 Chemical compound CCOC(OCC)P(O)(=O)CCCN QIIVUOWTHWIXFO-UHFFFAOYSA-N 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- -1 hexylmethyl Chemical group 0.000 description 2
- 210000002287 horizontal cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000005157 neural retina Anatomy 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000004256 retinal image Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- JYLNVJYYQQXNEK-UHFFFAOYSA-N 3-amino-2-(4-chlorophenyl)-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(CN)C1=CC=C(Cl)C=C1 JYLNVJYYQQXNEK-UHFFFAOYSA-N 0.000 description 1
- BLOIUFYKQCCAGP-UHFFFAOYSA-N 5-aminopentanoic acid;hydron;chloride Chemical compound Cl.NCCCCC(O)=O BLOIUFYKQCCAGP-UHFFFAOYSA-N 0.000 description 1
- BWXCECYGGMGBHD-UHFFFAOYSA-M 6-(6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl)-6h-furo[3,4-g][1,3]benzodioxol-8-one;bromide Chemical compound [Br-].C[N+]1(C)CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 BWXCECYGGMGBHD-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- 208000001692 Esotropia Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010061137 Ocular toxicity Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 206010048955 Retinal toxicity Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940124570 cycloplegic agent Drugs 0.000 description 1
- 230000003500 cycloplegic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004353 induced myopia Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000004315 low visual acuity Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000004423 myopia development Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 230000008928 neurochemical process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 231100000327 ocular toxicity Toxicity 0.000 description 1
- 210000001743 on-bipolar cell Anatomy 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 201000011195 retinal edema Diseases 0.000 description 1
- 230000004508 retinal signalling Effects 0.000 description 1
- 231100000385 retinal toxicity Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32965501P | 2001-10-16 | 2001-10-16 | |
| US60/329,655 | 2001-10-16 | ||
| PCT/US2002/032776 WO2003032975A1 (en) | 2001-10-16 | 2002-10-16 | Modulation of ocular growth and myopia by gaba drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2466800A1 true CA2466800A1 (en) | 2003-04-24 |
Family
ID=23286413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002466800A Abandoned CA2466800A1 (en) | 2001-10-16 | 2002-10-16 | Modulation of ocular growth and myopia by gaba drugs |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060264508A1 (https=) |
| EP (1) | EP1435938A4 (https=) |
| JP (1) | JP2005509623A (https=) |
| KR (1) | KR20040053181A (https=) |
| CN (1) | CN1604775A (https=) |
| CA (1) | CA2466800A1 (https=) |
| WO (1) | WO2003032975A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7266725B2 (en) | 2001-09-03 | 2007-09-04 | Pact Xpp Technologies Ag | Method for debugging reconfigurable architectures |
| DE19651075A1 (de) | 1996-12-09 | 1998-06-10 | Pact Inf Tech Gmbh | Einheit zur Verarbeitung von numerischen und logischen Operationen, zum Einsatz in Prozessoren (CPU's), Mehrrechnersystemen, Datenflußprozessoren (DFP's), digitalen Signal Prozessoren (DSP's) oder dergleichen |
| DE19654595A1 (de) | 1996-12-20 | 1998-07-02 | Pact Inf Tech Gmbh | I0- und Speicherbussystem für DFPs sowie Bausteinen mit zwei- oder mehrdimensionaler programmierbaren Zellstrukturen |
| DE19654593A1 (de) | 1996-12-20 | 1998-07-02 | Pact Inf Tech Gmbh | Umkonfigurierungs-Verfahren für programmierbare Bausteine zur Laufzeit |
| DE19654846A1 (de) | 1996-12-27 | 1998-07-09 | Pact Inf Tech Gmbh | Verfahren zum selbständigen dynamischen Umladen von Datenflußprozessoren (DFPs) sowie Bausteinen mit zwei- oder mehrdimensionalen programmierbaren Zellstrukturen (FPGAs, DPGAs, o. dgl.) |
| ATE243390T1 (de) | 1996-12-27 | 2003-07-15 | Pact Inf Tech Gmbh | Verfahren zum selbständigen dynamischen umladen von datenflussprozessoren (dfps) sowie bausteinen mit zwei- oder mehrdimensionalen programmierbaren zellstrukturen (fpgas, dpgas, o.dgl.) |
| DE19704728A1 (de) | 1997-02-08 | 1998-08-13 | Pact Inf Tech Gmbh | Verfahren zur Selbstsynchronisation von konfigurierbaren Elementen eines programmierbaren Bausteines |
| US6542998B1 (en) | 1997-02-08 | 2003-04-01 | Pact Gmbh | Method of self-synchronization of configurable elements of a programmable module |
| DE19704742A1 (de) | 1997-02-11 | 1998-09-24 | Pact Inf Tech Gmbh | Internes Bussystem für DFPs, sowie Bausteinen mit zwei- oder mehrdimensionalen programmierbaren Zellstrukturen, zur Bewältigung großer Datenmengen mit hohem Vernetzungsaufwand |
| US7003660B2 (en) | 2000-06-13 | 2006-02-21 | Pact Xpp Technologies Ag | Pipeline configuration unit protocols and communication |
| DE10081643D2 (de) | 1999-06-10 | 2002-05-29 | Pact Inf Tech Gmbh | Sequenz-Partitionierung auf Zellstrukturen |
| US8058899B2 (en) | 2000-10-06 | 2011-11-15 | Martin Vorbach | Logic cell array and bus system |
| AU2002220600A1 (en) | 2000-10-06 | 2002-04-15 | Pact Informationstechnologie Gmbh | Cell system with segmented intermediate cell structure |
| US6990555B2 (en) | 2001-01-09 | 2006-01-24 | Pact Xpp Technologies Ag | Method of hierarchical caching of configuration data having dataflow processors and modules having two- or multidimensional programmable cell structure (FPGAs, DPGAs, etc.) |
| US7844796B2 (en) | 2001-03-05 | 2010-11-30 | Martin Vorbach | Data processing device and method |
| US7210129B2 (en) | 2001-08-16 | 2007-04-24 | Pact Xpp Technologies Ag | Method for translating programs for reconfigurable architectures |
| US7581076B2 (en) | 2001-03-05 | 2009-08-25 | Pact Xpp Technologies Ag | Methods and devices for treating and/or processing data |
| US7444531B2 (en) | 2001-03-05 | 2008-10-28 | Pact Xpp Technologies Ag | Methods and devices for treating and processing data |
| US7996827B2 (en) | 2001-08-16 | 2011-08-09 | Martin Vorbach | Method for the translation of programs for reconfigurable architectures |
| US7434191B2 (en) | 2001-09-03 | 2008-10-07 | Pact Xpp Technologies Ag | Router |
| AU2003208266A1 (en) | 2002-01-19 | 2003-07-30 | Pact Xpp Technologies Ag | Reconfigurable processor |
| WO2003071432A2 (de) | 2002-02-18 | 2003-08-28 | Pact Xpp Technologies Ag | Bussysteme und rekonfigurationsverfahren |
| US20060142249A1 (en) * | 2002-06-28 | 2006-06-29 | Wolfgang Froestl | Ophthalmic use |
| US7657861B2 (en) | 2002-08-07 | 2010-02-02 | Pact Xpp Technologies Ag | Method and device for processing data |
| AU2003286131A1 (en) | 2002-08-07 | 2004-03-19 | Pact Xpp Technologies Ag | Method and device for processing data |
| WO2004038599A1 (de) | 2002-09-06 | 2004-05-06 | Pact Xpp Technologies Ag | Rekonfigurierbare sequenzerstruktur |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| FI20075498A7 (fi) | 2007-06-29 | 2008-12-30 | Eero Castren | Menetelmä amblyopian hoitamiseksi masennuslääkkeillä |
| WO2015009533A1 (en) | 2013-07-16 | 2015-01-22 | Allergan, Inc. | Gabaa receptor antagonists affecting ganglion cell function and visual function |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| CN116785286B (zh) * | 2020-10-10 | 2026-02-17 | 远大医学营养科学(武汉)有限公司 | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 |
| KR102747804B1 (ko) * | 2024-03-07 | 2024-12-31 | 주식회사 케이에스비튜젠 | 라세탐 계열 화합물을 유효성분으로 포함하는 눈 기능 장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
-
2002
- 2002-10-02 US US10/493,049 patent/US20060264508A1/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032776 patent/WO2003032975A1/en not_active Ceased
- 2002-10-16 JP JP2003535779A patent/JP2005509623A/ja active Pending
- 2002-10-16 KR KR10-2004-7005660A patent/KR20040053181A/ko not_active Withdrawn
- 2002-10-16 CA CA002466800A patent/CA2466800A1/en not_active Abandoned
- 2002-10-16 CN CNA028251512A patent/CN1604775A/zh active Pending
- 2002-10-16 EP EP02801699A patent/EP1435938A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN1604775A (zh) | 2005-04-06 |
| JP2005509623A (ja) | 2005-04-14 |
| WO2003032975A1 (en) | 2003-04-24 |
| EP1435938A4 (en) | 2007-12-26 |
| EP1435938A1 (en) | 2004-07-14 |
| US20060264508A1 (en) | 2006-11-23 |
| KR20040053181A (ko) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060264508A1 (en) | Modulation of ocular growth and myopia by gaba drugs | |
| Stone et al. | Effects of nicotinic antagonists on ocular growth and experimental myopia | |
| Stone et al. | GABA, experimental myopia, and ocular growth in chick | |
| RU2440110C2 (ru) | Лечение воспалительных заболеваний | |
| McBrien et al. | Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. | |
| Tigges et al. | Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys | |
| EP1100480B1 (en) | Muscarinic antagonists in the treatment of presbyopia | |
| Broft et al. | Baclofen for binge eating: An open‐label trial | |
| Kaiti et al. | Role of atropine in the control of myopia progression-a review | |
| Stone et al. | Postnatal control of ocular growth: dopaminergic mechanisms | |
| US10888556B2 (en) | Method for treating myopia with an nsaid and an anti-muscarinic agent | |
| EP0422068B1 (en) | Pharmacological treatment of ocular development | |
| CA2075833C (en) | Neuropeptide control of ocular growth | |
| Yang et al. | Prostaglandin F2α receptor modulation affects eye development in guinea pigs | |
| CA2160798C (en) | Gaba-ergic modulation of eye growth | |
| AU2002362928A1 (en) | Modulation of ocular growth and myopia by GABA drugs | |
| CN119454701A (zh) | 一种含西维美林的眼用制剂及其制备方法和应用 | |
| Zeller et al. | Enzymology of the refractory media of the eye: IX. On the role of monoamine oxidase in the regulation of aqueous humor dynamics of the rabbit eye | |
| US20050171139A1 (en) | Treating psychotic symptoms | |
| OPTICA et al. | patients with Rasmussen encephalitis have antibodies to the glutamate receptor. 58. A | |
| CN119700756A (zh) | 一种眼用药物组合物及其用途 | |
| Tripathy | Interactions between GABAergic, dopaminergic and cholinergic neurotransmitter systems in form deprived myopic chick | |
| RU2244528C1 (ru) | Способ терапевтического лечения первичной открытоугольной глаукомы | |
| Zhou et al. | 518 Factors mediating myopia | |
| Keli Long et al. | Effects of Dopaminergic Agents on Progression of Naturally Occurring 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |